BioStem Technologies stock analysis
Want to see BSEM full AI Analyst Report?
BioStem Technologies (BSEM) Stock Price & Analysis
BSEM Stock Chart & Stats
- Day’s Range
- $0.90 - $1.25
- 52-Week Range
- $0.90 - $8.40
- Previous Close
- $1.30
- Volume
- N/A
- Average Volume (3M)
- 220.59K
- Market Cap
- $20.14M
- Enterprise Value
- $55.39M
- Total Cash (Recent Filing)
- $971.14K
- Total Debt (Recent Filing)
- $1.17M
- Price to Earnings (P/E)
- ―
- Beta
- 1.88
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- -0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broader Customer Adoption
Increasing adoption across multiple product lines strengthens customer integration and revenue breadth. Because customers buying more than one line already contribute over half of revenue, deeper product penetration could support retention, cross-selling and more durable commercial growth.
Expanded Hospital Distribution
GPO access expands procurement availability through established hospital contracting channels and can reduce barriers to adoption. Combined with the company’s focus on hospital revenue, this creates a more scalable route for VENDAJE to reach institutional customers over coming quarters.
Planned Margin Improvement
Moving production in-house could improve economics by reducing reliance on current transfer pricing and increasing control over manufacturing. If process validation and regulatory requirements are completed successfully, the planned margin expansion would strengthen operating leverage and future cash-generation potential.
Bears Say
Severe Liquidity Pressure
A sharply reduced cash balance alongside accelerating operating cash use leaves limited financial flexibility while the business remains loss-making. This increases dependence on financing or asset alternatives and could constrain investment, execution and the company’s ability to absorb further setbacks.
Unprofitable Operating Model
Deep current losses indicate that the commercial model is not yet producing sustainable earnings and that performance has deteriorated substantially from profitable 2024 results. Persistent losses could consume capital, weaken financial resilience and make the planned operating improvements harder to deliver.
Margin And Revenue Contraction
Sequential revenue and gross-margin declines show pressure on both demand and unit economics, particularly during the BioTissue transition. Although management expects improvement later, weaker current contribution limits operating leverage and makes near-term progress dependent on successful execution.
BioStem Technologies News
BioStem Updates BR-AC Wound-Healing Study: What BSEM Investors Should Know
BioStem Technologies ($BSEM) announced an update on their ongoing clinical study. Study Overview: BioStem Technologies (BSEM) updated its study, officially titled “A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous
BioStem’s BR-AM Trial Completion Sets the Stage for Next Moves in Diabetic Wound Care
BioStem Technologies ($BSEM) announced an update on their ongoing clinical study. The study A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or
BSEM FAQ
What was BioStem Technologies’s price range in the past 12 months?
What is BioStem Technologies’s market cap?
When is BioStem Technologies’s upcoming earnings report date?
How were BioStem Technologies’s earnings last quarter?
Is BioStem Technologies overvalued?
Does BioStem Technologies pay dividends?
What is BioStem Technologies’s EPS estimate?
How many shares outstanding does BioStem Technologies have?
What happened to BioStem Technologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioStem Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Matuszewski
- Employees
- 73
- Website
- biostemtechnologies.com
- Address
- 4901 Northwest 17th Way, Fort Lauderdale, FL, 33309, US
BioStem Technologies (BSEM) Earnings & Revenues
BSEM Earnings Call
Earnings Call SentimentNeutral
The call presented meaningful operational and commercial progress, including hospital revenue growth, stronger multi-product adoption, expanded GPO access, completed systems integration, raised 2026 revenue guidance and planned cost and manufacturing initiatives. However, these positives were balanced by declining total revenue, lower gross margins, higher operating expenses, a widening net and adjusted EBITDA loss, reduced cash, increased operating cash use and an outstanding BioTissue payment. The overall tone was cautiously optimistic about the 2027 plan but acknowledged substantial near-term financial and liquidity challenges.
View all BSEM earnings summariesBSEM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |










